Zacks Investment Research upgraded shares of DENTSPLY SIRONA (NASDAQ:XRAY) from a hold rating to a buy rating in a research report released on Saturday, Zacks.com reports. Zacks Investment Research currently has $61.00 target price on the medical instruments supplier’s stock.
According to Zacks, “DENTSPLY ended the first quarter on a solid note, with earnings and revenues beating estimates. The company gained from the core Technology & Equipment unit, which witnessed a year-over-year upside in the quarter. Sales in the United States also grew year over year. A series of product launches in the first quarter buoy optimism in the stock. The company narrowed the EPS guidance for 2019. The stock outperformed the industry in a year’s time. Meanwhile, DENTSPLY’s Consumable revenues witnessed a year-over-year downside in the quarter. In fact, the company’s quarterly revenues also declined in the first quarter. International revenues decreased on a year-over-year basis as well. Additionally, unfavorable foreign exchange and restructuring costs are expected to mar DENTSPLY’s top line, going forward. The stock is overvalued at the moment.”
A number of other research firms have also weighed in on XRAY. ValuEngine upgraded shares of DENTSPLY SIRONA from a hold rating to a buy rating in a research report on Saturday, May 4th. HC Wainwright restated a neutral rating and set a $55.00 target price (up from $49.00) on shares of DENTSPLY SIRONA in a research report on Monday, May 6th. Barrington Research upgraded shares of DENTSPLY SIRONA from a market perform rating to an outperform rating and set a $63.00 target price on the stock in a research report on Monday, May 6th. BidaskClub upgraded shares of DENTSPLY SIRONA from a hold rating to a buy rating in a research report on Tuesday, April 16th. Finally, Robert W. Baird boosted their target price on shares of DENTSPLY SIRONA from $42.00 to $50.00 and gave the stock a neutral rating in a research report on Monday, March 4th. Eight investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $53.65.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Friday, May 3rd. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.10. DENTSPLY SIRONA had a negative net margin of 26.48% and a positive return on equity of 8.99%. The firm had revenue of $946.20 million for the quarter, compared to analyst estimates of $925.13 million. During the same period last year, the firm posted $0.45 EPS. DENTSPLY SIRONA’s quarterly revenue was down 1.0% on a year-over-year basis. Analysts forecast that DENTSPLY SIRONA will post 2.34 earnings per share for the current fiscal year.
In other DENTSPLY SIRONA news, SVP Daniel P. Key acquired 3,697 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were acquired at an average cost of $54.68 per share, for a total transaction of $202,151.96. Following the transaction, the senior vice president now directly owns 9,024 shares of the company’s stock, valued at $493,432.32. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Eric Brandt sold 9,160 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $53.45, for a total transaction of $489,602.00. Following the completion of the sale, the director now owns 26,003 shares in the company, valued at $1,389,860.35. The disclosure for this sale can be found here. Insiders have sold a total of 101,022 shares of company stock worth $5,535,985 over the last 90 days. Insiders own 0.62% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Hanseatic Management Services Inc. purchased a new stake in shares of DENTSPLY SIRONA in the 1st quarter worth about $30,000. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of DENTSPLY SIRONA in the 4th quarter worth about $26,000. Private Capital Group LLC boosted its position in shares of DENTSPLY SIRONA by 105.3% in the 4th quarter. Private Capital Group LLC now owns 700 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 359 shares in the last quarter. Pinnacle Bank purchased a new stake in shares of DENTSPLY SIRONA in the 4th quarter worth about $26,000. Finally, Truehand Inc purchased a new stake in shares of DENTSPLY SIRONA in the 4th quarter worth about $27,000. Institutional investors and hedge funds own 99.78% of the company’s stock.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Featured Article: Strangles
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.